kras mutant inhibitor qtx3544
Generic: KRAS Mutant Inhibitor QTX3544
kras mutant inhibitor qtx3544: 1 clinical trial tracked.
kras mutant inhibitor qtx3544 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about kras mutant inhibitor qtx3544, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Primary endpoint: Number of participants with Treatment-emergent Adverse Events (TEAEs)
Interventionalopen237 targetStarted 2025-01Completion 2029-0110 sites · United StatesQuanta Therapeutics